Zai Lab Ltd (ZLAB): R&D Expense
$220.90M
Year ended 2025-12-31
$236.92M
Trailing 12 months to 2026-06-30
-8.3%
3-year compound annual growth
-0.2%
5-year compound annual growth
+32.2%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $220.90M | -5.8% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $234.50M | -11.8% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $265.87M | -7.2% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $286.41M | -50.0% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $573.31M | +157.4% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $222.71M | +56.6% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $142.22M | +18.2% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $120.28M | +205.7% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $39.34M | +22.4% | 2020-04-29, From 2017-01-01 |
| 2016-12-31 | $32.15M | +136.6% | 2019-03-29, From 2016-01-01 |
| 2015-12-31 | $13.59M | n/a | 2018-04-30, From 2015-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $220.90M | -5.8% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $206.01M | -5.3% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $451.95M | -10.8% |
| Innoviva, Inc. (INVA) | 2025-12-31 | $30.60M | +124.1% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $71.53M | +36.7% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $186.18M | +32.4% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $216.18M | -20.1% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $148.29M | -30.1% |
Compare ZLAB, NATR, TVTX, BBIO side by side · Screen every company in Pharmaceutical Preparations ↗